SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Sept. 25, 2018
JERSEY CITY, N.J., Sept. 25, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:
- The Ladenburg Thalmann 2018 Healthcare Conference at the Sofitel New York on Tuesday, October 2, 2018 at 10:30 a.m. ET.
- Cantor Fitzgerald's Global Healthcare Conference at InterContinental New York Barclay on Wednesday, October 3, 2018 at 2:15 p.m. ET.
Live webcasts of the presentations will be available on the Investors section of the Company's website: www.scynexis.com. A replay of each presentation will be available approximately two hours after the event and will be available for two weeks following each presentation.
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
George E. MacDougall
MacDougall Biomedical Communications
SOURCE SCYNEXIS, Inc.